Travere Therapeutics (NASDAQ:TVTX) is in focus after a fresh update tied to rare disease therapies, with market attention on ...

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced it will report second quarter 2026 financial results on Tuesday, August 4, 2026, after the close of the U.S. financial markets. The Company ...

Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Travere Therapeutics, Inc. (NASDAQ: TVTX) breached their fiduciary duties to shareholders ...

The Second Circuit closed the books on a novel issue that arose after Evan Greebel was convicted of securities fraud—whether ...

TransMedics Group, Inc. ("TransMedics") , a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the ...

Artivion, Inc. , a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will ...

LGND stock has risen more than 56.5% so far in 2026. Ligand doesn't make drugs; it forks over funding in exchange for Big ...

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm ...

Using a continuous glucose monitor improved time in range with no increase in hypoglycemia for people with type 2 diabetes ...

With its focus on small-cap companies and exposure to China, The Biotech Growth Trust (BIOG) is one such example. Over the past year, the trust’s total shareholder return was 105 per cent – double the ...